Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements Of Operations

 v2.3.0.11
Condensed Consolidated Statements Of Operations (USD $)
In Thousands, except Share data
3 Months Ended 6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Jun. 30, 2010
Revenues:        
Royalties $ 2,172 $ 1,601 $ 4,165 $ 3,563
Material sales 2,984 0 4,034 0
Collaborative research and development and other revenues 2,307 4,237 3,160 8,233
Total revenues 7,463 5,838 11,359 11,796
Operating costs and expenses:        
Cost of sales 1,623 0 2,148 0
Research and development 3,237 6,602 5,223 13,963
General and administrative 3,855 3,290 8,034 6,338
Lease exit and termination costs (16) 0 (168) 0
Total operating costs and expenses 8,699 9,892 15,237 20,301
Accretion of deferred gain on sale leaseback 426 426 851 851
Loss from operations (810) (3,628) (3,027) (7,654)
Other income (expense):        
Interest income 0 118 30 328
Interest expense (674) (13) (1,093) (31)
Decrease (increase) in liability for contingent value rights 679 3,690 (1,057) 4,242
Other, net 32 168 82 734
Total other income (expense), net 37 3,963 (2,038) 5,273
Income (loss) before income taxes (773) 335 (5,065) (2,381)
Income tax expense (benefit) 141 625 (13,637) 899
Income (loss) from continuing operations (914) (290) 8,572 (3,280)
Discontinued operations:        
Discontinued operations 0 7 4 246
Net income (loss): (914) (283) 8,576 (3,034)
Basic and diluted per share amounts:        
Income (loss) from continuing operations $ (0.05) $ (0.01) $ 0.44 $ (0.16)
Discontinued operations $ 0.00 $ 0.00 $ 0.00 $ 0.01
Net income (loss) $ (0.05) $ (0.01) $ 0.44 $ (0.15)
Weighted average number of common shares - basic 19,650,260 19,608,685 19,623,249 19,595,784
Weighted average number of common shares - diluted 19,650,260 19,608,685 19,637,983 19,595,784
AVINZA Product Line [Member]
       
Discontinued operations:        
Gain on sale of a product line 0 3 0 13
Onocology Product Line [Member]
       
Discontinued operations:        
Gain on sale of a product line $ 0 $ 4 $ 4 $ 233